Evonik's Independence Test: Union Pressure on RAG-Stiftung Meets a Sharper Earnings Picture
Published on 11/20/2026 at 19:10 | Editorial boerse-global.deEvonik's decision to stay solo has opened a second front. With BASF gone, the chemical maker's largest shareholder is now in the union's crosshairs — and the company's own third-quarter numbers are being read as the yardstick for whether going it alone can work.
IG BCE is pressing the RAG-Stiftung to help bankroll Evonik's restructuring and to free up additional investment. In an internal letter reported by Handelsblatt, Michael Vassiliadis and Alexander Bercht accuse the foundation of having paid dividends partly out of the company's substance. The union's demands go beyond a contribution to restructuring costs: it also wants changes to the foundation's governance and investment strategy.
A 25.1% Floor, Written Into the Statute
The RAG-Stiftung intends to cut its stake step by step to 25.1%. IG BCE wants that minimum holding anchored permanently in the foundation's charter — turning the dispute from a question of how many shares the foundation will keep into one of how binding its commitment remains. The foundation's rationale for the sell-down is different: it aims to build up other capital investments to fund the follow-on costs of Germany's ended hard-coal mining. It said today it regretted that the two boards had not held deeper talks before the takeover efforts collapsed.
Evonik's interim chief, Claus Rettig, is meanwhile betting on the specialty chemicals group's standalone development. BASF ended its pursuit yesterday after Evonik rejected two non-binding cash offers, the last at EUR 24 per share. BASF had held out the prospect of a further moderate increase but saw no basis for a higher price in Evonik's standalone business prospects and the risks attached.
Should investors sell immediately? Or is it worth buying Evonik?
The Market's Verdict
Oddo BHF downgraded Evonik to "Neutral" today and cut its price target to EUR 19 from EUR 22, seeing only limited upside after BASF's withdrawal. Bernstein analyst James Hooper, by contrast, considers later talks possible if Evonik approaches BASF.
The stock had reached its 52-week high of EUR 22.52 on 18 November, closed yesterday at EUR 18.30 and stood at EUR 18.17 today. With the takeover fantasy gone, the business itself is back in focus — and the third-quarter figures make a clear case. Adjusted EBITDA from continuing operations came in at around EUR 630 million, up roughly 40% from just under EUR 450 million a year earlier. Evonik has also sharpened its guidance: adjusted EBITDA for 2026 is to land in the upper half of the EUR 2.0–2.2 billion range, after close to EUR 1.9 billion in 2025.
The bottom line still showed a loss of EUR 53 million for the quarter, against EUR 106 million a year before. A large chunk of that is the roughly EUR 310 million restructuring charge booked in connection with the expansion of the group's overhaul program — about half the quarter's adjusted EBITDA.
Two Open Questions
Whether the earnings jump holds is one. Evonik attributes the increase mainly to prices and expects that tailwind to fade; profit growth from higher prices can shrink faster than gains from volume or permanently lower costs, and a single strong quarter cannot show how much survives once pricing stops helping. For the full year the group is steering toward the upper half of the range — even its midpoint of EUR 2.1 billion would sit around 12% above the prior-year figure.
The second is that the restructuring is not yet fully mapped out. In the program's second phase, some 3,200 more jobs are to go worldwide between 2027 and 2029, around 2,150 of them in Germany. Evonik is still working out the detailed measures, and aims to have them ready by the end of 2026.
Evonik at a turning point? This analysis reveals what investors need to know now.
For the business, that cuts both ways. Operating profit is clearly above the prior year and the annual target has become more concrete and more demanding — the base from which Evonik can tackle the overhaul under its own steam. At the same time, phase two lies ahead, its details are unfinished, and adjusted earnings power has yet to prove itself in a period when prices contribute less.
BASF's pointed reference to the risks of the solo route touches something real but does not change the starting position: Evonik enters independence operationally strengthened. The higher adjusted result and the sharpened guidance underpin the standalone plan; the costs of the overhaul and the durability of earnings remain its risks. When Evonik publishes its report for full-year 2026 on 4 March 2027, at least EUR 2.1 billion in adjusted EBITDA would confirm the operating strength — though it would say nothing yet about the long-term success of the restructuring.
Ad
Evonik Stock: New Analysis - 20 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
